Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and…

cnbc.com6 mesi fa

Obesity assets represent about 25% of total forecast sales of the late-stage pipeline, while oncology's share has slipped to 20%,…

cnbc.com10 g fa

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster…

cnbc.com9 mesi fa

Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.

cnbc.com2 mesi fa

Eli Lilly's fourth-quarter earnings come as it tries to maintain its advantage over Novo Nordisk in the GLP-1 market.

cnbc.com3 mesi fa

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

cnbc.com14 g fa

Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro | Fortune